BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28007318)

  • 1. Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines.
    Kunnimalaiyaan S; Sokolowski K; Gamblin TC; Kunnimalaiyaan M
    Am J Surg; 2017 Apr; 213(4):645-651. PubMed ID: 28007318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
    Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
    Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase.
    Liao B; Liang H; Chen J; Liu Q; Zhang B; Chen X
    Tumour Biol; 2015 Dec; 36(12):9347-56. PubMed ID: 26108995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.
    Ocker M; Alajati A; Ganslmayer M; Zopf S; Lüders M; Neureiter D; Hahn EG; Schuppan D; Herold C
    J Cancer Res Clin Oncol; 2005 Jun; 131(6):385-94. PubMed ID: 15754201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
    Lu YS; Kashida Y; Kulp SK; Wang YC; Wang D; Hung JH; Tang M; Lin ZZ; Chen TJ; Cheng AL; Chen CS
    Hepatology; 2007 Oct; 46(4):1119-30. PubMed ID: 17654699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients.
    Hsieh YH; Su IJ; Yen CJ; Tsai TF; Tsai HW; Tsai HN; Huang YJ; Chen YY; Ai YL; Kao LY; Hsieh WC; Wu HC; Huang W
    Carcinogenesis; 2013 Feb; 34(2):475-85. PubMed ID: 23172669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects and mechanism of suberoylanilide hydroxamic acid on the proliferation and apoptosis of human hepatoma cell line Bel-7402.
    Wang YC; Kong WZ; Xing LH; Yang X
    J BUON; 2014; 19(3):698-704. PubMed ID: 25261655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.
    Yang B; Yu D; Liu J; Yang K; Wu G; Liu H
    Tumour Biol; 2015 Jul; 36(7):5051-61. PubMed ID: 25649979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
    Zhou X; Yang XY; Popescu NC
    Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suberoylanilide hydroxamic acid represses glioma stem-like cells.
    Hsu CC; Chang WC; Hsu TI; Liu JJ; Yeh SH; Wang JY; Liou JP; Ko CY; Chang KY; Chuang JY
    J Biomed Sci; 2016 Nov; 23(1):81. PubMed ID: 27863490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma.
    Srinivas C; Swathi V; Priyanka C; Anjana Devi T; Subba Reddy BV; Janaki Ramaiah M; Bhadra U; Bhadra MP
    Apoptosis; 2016 Nov; 21(11):1249-1264. PubMed ID: 27502208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Decitabine (5-aza-2'-deoxycytidine, 5-aza-CdR) in Comparison with Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) on DNMT1, DNMT3a and DNMT3b, HDAC 1-3, SOCS 1, SOCS 3, JAK2, and STAT3 Gene Expression in Hepatocellular Carcinoma HLE and LCL-PI 11 Cell Lines.
    Sanaei M; Kavoosi F; Pourahmadi M
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2089-2098. PubMed ID: 34319031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of SAHA on proliferation and apoptosis of hepatocellular carcinoma cells and hepatitis B virus replication.
    Wang YC; Yang X; Xing LH; Kong WZ
    World J Gastroenterol; 2013 Aug; 19(31):5159-64. PubMed ID: 23964152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells.
    Xu XD; Yang L; Zheng LY; Pan YY; Cao ZF; Zhang ZQ; Zhou QS; Yang B; Cao C
    BMC Cancer; 2014 May; 14():373. PubMed ID: 24886166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation.
    Carlisi D; Lauricella M; D'Anneo A; Emanuele S; Angileri L; Di Fazio P; Santulli A; Vento R; Tesoriere G
    Eur J Cancer; 2009 Sep; 45(13):2425-38. PubMed ID: 19643600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
    Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
    Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.
    Gillenwater AM; Zhong M; Lotan R
    Mol Cancer Ther; 2007 Nov; 6(11):2967-75. PubMed ID: 18025281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.